DRUG REGULATORY AUTHORITY OF PAKISTAN
DIVISION OF QUALITY ASSURANCE & LABORATORY TESTING

MEDICAL PRODUCT ALERT

DRAP ALERT NO. Nº I/S/11-26-65

Substandard Preva-28F Tablet by M/s Aries Pharmaceuticals, Peshawar

Date: 26th November, 2026

Target Audience:

- National Regulatory Field Force of DRAP and Provincial Drug Control Departments.
- Healthcare Professionals (Physicians, Pharmacists & Nurses).
- General Public.

Alert Summary:

The Central Drugs Laboratory (CDL), Karachi has declared the below-mentioned samples as "Substandard" based on the results of the content uniformity test. Following are the details:

S#	Product Name	Batch	Manufacturer	Remarks
1.	Preva-28F Tablet Levonorgestrel…….0.15mg Ethinyl Estradiol…..0.03mg Ferrous Fumarate….75mg	8186 8181	Aries Pharmaceuticals (Pvt) Ltd., W-1, Industrial Estate, Hayatabad, Peshawar	The drug product has been declared as Substandard on the basis of content uniformity test.

Risk Statement:

Considering the critical role of dose consistency in hormonal contraceptive products, the affected batches pose a high risk to public health due to the potential for reduced contraceptive efficacy and associated clinical consequences.

Action initiated: -

The Provincial Drug Control departments have been asked to immediately conduct market surveys for detection of presence and removal of mentioned batches from the market.

Advice for Pharmacies/Medical stores: -

All pharmacists and chemist working at distributions and pharmacies should **immediately check** their stocks and stop supplying mentioned products. The remaining stocks should be quarantined and returned to the supplier/company. Regulatory field force of all federating units (DRAP and Provincial Health Departments) should also increase surveillance in the market to ensure the effective recall of defective products(s).

Advice for Healthcare Professionals: -

DRAP requests increased vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by batches of mentioned products. Adverse reactions or quality problems experienced with the use of above mentioned product are to be reported to the National Pharmacovigilance Centre (NPC), DRAP using Adverse

Event Reporting Form or online through this link. Further information of reporting problems to DRAP is available on this link.

Advice for Consumers/general public: -

Consumers should stop using products bearing the affected batch number(s) and shall contact to their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product, and report the incident to Drug Regulatory Authority of Pakistan/ National Pharmacovigilance Centre.

Drug Regulatory Authority of Pakistan
محفوظ، موئثر اور معیاری اشیائے